Tonix Pharmaceuticals Holding CORP. 8-K Filing
Ticker: TNXP · Form: 8-K · Filed: Nov 21, 2025 · CIK: 1430306
Sentiment: neutral
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2025-11-21 16:48:12
Key Financial Figures
- $150,000,000 — issuable under the Sales Agreement from $150,000,000 to $400,000,000. A copy of the legal op
- $400,000,000 — he Sales Agreement from $150,000,000 to $400,000,000. A copy of the legal opinion as to the
Filing Documents
- tnxp-8k_112125.htm (8-K) — 24KB
- ex-1.htm (EX-1) — 16KB
- ex-5.htm (EX-5) — 13KB
- brownsteinlogo.jpg (GRAPHIC) — 6KB
- 0001999371-25-018392.txt ( ) — 232KB
- tnxp-20251121.xsd (EX-101.SCH) — 3KB
- tnxp-20251121_lab.xml (EX-101.LAB) — 33KB
- tnxp-20251121_pre.xml (EX-101.PRE) — 22KB
- tnxp-8k_112125_htm.xml (XML) — 3KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. On November 21, 2025, Tonix Pharmaceuticals Holding Corp. (the "Company") amended its Sales Agreement with A.G.P./Alliance Global Partners, dated as of June 11, 2025 (as amended, the "Sales Agreement"), to allow for an increase to the maximum aggregate offering price of shares issuable under the Sales Agreement (the "Amendment"). The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is attached as Exhibit 1.01 to this Current Report on Form 8-K and incorporated by reference into this Item 1.01.
01. Other Events
Item 8.01. Other Events. The Company increased the maximum aggregate offering price of the shares issuable under the Sales Agreement from $150,000,000 to $400,000,000. A copy of the legal opinion as to the legality of the shares issuable under the Sales Agreement is filed as Exhibit 5.01 attached hereto.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit No. Description. 1.01 5.01 23.01 104 Amendment No. 1 to Sales Agreement, dated November 21, 2025 Opinion of Brownstein Hyatt Farber Schreck, LLP Consent of Brownstein Hyatt Farber Schreck, LLP (included in Exhibit 5.01) Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TONIX PHARMACEUTICALS HOLDING CORP. Date: November 21, 2025 By: /s/ Bradley Saenger Bradley Saenger Chief Financial Officer